TABLE 1

Baseline and tumour characteristics in stair-climbing test groups

All patients<11 m stairs>12 m stairsp-value
Subjects n28366217
Age years71 (64–76)71 (66–76)71 (64–76)0.404
BMI kg·m−226.1±4.427.4±6.125.7±3.70.033
Male180 (63.6)39 (59.1)141 (65)0.384
Charlson comorbidity index0.012
 074 (26.1)6 (9.1)68 (31.3)
 179 (27.9)22 (33.3)57 (26.3)
 259 (20.8)16 (24.2)43 (19.8)
 3–451 (18.0)13 (19.7)38 (17.5)
 5 or higher20 (7.1)9 (13.6)11 (5.1)
Smoking history0.017
 Never54 (19.1)10 (15.2)44 (20.3)
 Former117 (41.3)20 (30.3)92 (42.4)
 Current112 (39.6)36 (54.5)74 (34.1)
Stair-climbing height m12.9±2.78.8±3.014.1±0.4<0.001
VO2max mL·kg−1·min−1 (n=36)15.2±19.412.8±1.619.1±3.7<0.001
FEV1 % pred80.8±19.471.6±17.781.9±18.7<0.001
ppoFEV1 %67.7±17.360.6±14.769.7±17.6<0.001
DLCO %79.7±19.372.7±19.781.9±18.70.001
ppoDLCO %67.3±17.162.3±16.267.6±17.40.006
Histology0.001
 Adenocarcinoma168 (59.4)27 (40.9)141 (65)
 Squamous cell cancer81 (28.6)30 (45.5)51 (23.5)
 Other33 (11.7)9 (13.6)25 (11.5)
Tumour size cm2.3 (1.5–4.0)2.6 (1.8–4.1)2.2 (1.5–4.0)0.135
PET-CT218 (77.0)53 (80.3)165 (76)0.471
Invasive staging67 (23.7)17 (25.8)50 (23)0.649
Pathological UICC stage#0.865
 I174 (61.5)42 (63.6)132 (60.8)
 II67 (23.7)14 (21.2)53 (24.4)
 III–IV42 (14.8)10 (15.2)32 (14.7)

Data are presented as median (interquartile range), mean±sd or n (%), unless otherwise stated. BMI: body mass index; VO2max: maximal oxygen uptake; FEV1: forced expiratory volume in 1 s; ppo: predicted post-operative; DLCO: diffusing capacity of the lung for carbon monoxide; PET-CT: positron emission tomography–computed tomography; UICC: Union for International Cancer Control. #: patients who received neoadjuvant treatment were classified according to clinical stage.